164 related articles for article (PubMed ID: 19451137)
21. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
[TBL] [Abstract][Full Text] [Related]
22. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
23. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone.
Proudman SM; Conaghan PG; Richardson C; Griffiths B; Green MJ; McGonagle D; Wakefield RJ; Reece RJ; Miles S; Adebajo A; Gough A; Helliwell P; Martin M; Huston G; Pease C; Veale DJ; Isaacs J; van der Heijde DM; Emery P
Arthritis Rheum; 2000 Aug; 43(8):1809-19. PubMed ID: 10943871
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
25. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage.
Lard LR; Boers M; Verhoeven A; Vos K; Visser H; Hazes JM; Zwinderman AH; Schreuder GM; Breedveld FC; De Vries RR; van der Linden S; Zanelli E; Huizinga TW
Arthritis Rheum; 2002 Apr; 46(4):899-905. PubMed ID: 11953965
[TBL] [Abstract][Full Text] [Related]
26. Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study.
van Tuyl LH; Plass AM; Lems WF; Voskuyl AE; Kerstens PJ; Dijkmans BA; Boers M
J Rheumatol; 2009 Jul; 36(7):1380-6. PubMed ID: 19487259
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK
Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
[TBL] [Abstract][Full Text] [Related]
28. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Sharp JT; Strand V; Leung H; Hurley F; Loew-Friedrich I
Arthritis Rheum; 2000 Mar; 43(3):495-505. PubMed ID: 10728741
[TBL] [Abstract][Full Text] [Related]
29. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Clin Exp Rheumatol; 2016; 34(6):1065-1071. PubMed ID: 27607411
[TBL] [Abstract][Full Text] [Related]
30. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
31. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
Schipper LG; Fransen J; Barrera P; Van Riel PL
Rheumatology (Oxford); 2009 Jul; 48(7):828-33. PubMed ID: 19458163
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial.
Lucassen MJJ; Ter Wee MM; den Uyl D; Konijn NPC; Nurmohamed MT; Voskuyl AE; van Schaardenburg D; Kerstens PJSM; Bultink IEM; Boers M; Lems WF
Osteoporos Int; 2021 Jul; 32(7):1441-1449. PubMed ID: 33464392
[TBL] [Abstract][Full Text] [Related]
35. The COBRA trial 20 years later.
Boers M
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S46-51. PubMed ID: 22018183
[TBL] [Abstract][Full Text] [Related]
36. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V; Korpela M; Laasonen L; Kautiainen H; Järvenpää S; Hannonen P; Leirisalo-Repo M; Blåfield H; Puolakka K; Karjalainen A; Möttönen T;
Arthritis Res Ther; 2010; 12(3):R122. PubMed ID: 20576092
[TBL] [Abstract][Full Text] [Related]
37. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
[TBL] [Abstract][Full Text] [Related]
38. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
39. Is attenuated COBRA treatment strategy (COBRA-light) non-inferior or not non-inferior than original COBRA strategy?
Akar S; Tinazli M
Clin Exp Rheumatol; 2014; 32(6 Suppl 87):S-18. PubMed ID: 25327510
[No Abstract] [Full Text] [Related]
40. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
